3 May 2023 - - US-based gene therapy company Avrobio, Inc. (NASDAQ: AVRO) has appointed Erik Ostrowski as interim chief executive officer effective as of May 1, the company said.

Ostrowski, who will continue as Avrobio's chief financial officer, succeeds founding president and CEO Geoff MacKay, who is leaving to join an emerging early-stage company.

The board of directors has begun a search to identify a permanent CEO, the company said.

Erik brings more than 20 years of finance and biotech operating experience, including a focus on rare diseases and cell-based therapies. He is also currently a member of the board of directors of Faron Pharmaceuticals.

Prior to joining Avrobio, Erik was CFO at Summit Therapeutics, where he played a key role in executing the company's NASDAQ initial public offering, completing multiple strategic transactions and building out the company's US operations.

Prior to joining Summit, Erik was vice president of finance at Organogenesis Inc. He previously worked in investment banking, including as a director of healthcare investment banking with Leerink Partners.

Erik began his career at PricewaterhouseCoopers and received a BS in accounting and economics from Babson College and an MBA from the University of Chicago Booth School of Business.